Gyroscope Therapeutics announced the company has entered a sponsored research agreement with the University of Pennsylvania and the Penn Center for Advanced Retinal and Ocular Therapeutics (CAROT) to develop gene therapies for serious eye diseases that can lead to permanent vision loss. Gyroscope has an exclusive option to the intellectual property associated with, and arising from, the research conducted under the agreement.
A team of researchers from CAROT and Gyroscope will work together to explore specific gene therapy targets for glaucoma, optic neuritis, and retinitis pigmentosa. The CAROT team is led by Jean Bennett, MD, PhD, the F.M. Kirby Professor of Ophthalmology, along with Ken Shindler, MD, PhD, an Associate Professor of Ophthalmology and Ahmara Ross, MD, PhD, an Assistant Professor of Ophthalmology, of the Perelman School of Medicine.
“Too many people around the globe face a life with limited vision or complete blindness because current treatment options for many serious eye diseases are so limited,” Khurem Farooq, Chief Executive Officer, Gyroscope, said in a company news release. “Gene therapy has the potential to be a completely new way of approaching these diseases, and we are very excited to work with Jean and the team of world leaders in ophthalmic gene therapy research at the University of Pennsylvania to evaluate new targets for these conditions.”
“Our team is passionate about the potential of gene therapies for people with serious eye diseases,” said Dr. Bennett. “We are looking forward to furthering our research in glaucoma, optic neuritis and retinitis pigmentosa, which combined currently cause a devastating loss of vision for millions of people around the world.”